Patents by Inventor Kenneth Dale Brady

Kenneth Dale Brady has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfonamide interleukin-1beta converting enzyme inhibitors
    Publication number: 20020156094
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.
    Type: Application
    Filed: September 25, 2001
    Publication date: October 24, 2002
    Applicant: Warner-Lambert Company
    Inventors: Hans P. Albrecht, Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Catherine Rose Kostlan, Bruce David Roth, Nigel Walker
  • Sulfonamide interleukin-1&bgr; converting enzyme inhibitors
    Patent number: 6316415
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1&bgr; converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1&bgr; converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: November 13, 2001
    Assignees: BASF Aktiengesellschaft, Warner-Lambert Company
    Inventors: Hans P. Albrecht, Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Catherine Rose Kostlan, Bruce David Roth, Nigel Walker
  • Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors
    Patent number: 6083981
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula I, II, or III. ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Elizabeth Ann Lunney, Mark Stephen Plummer, Tomi Sawyer, Aurash Shahripour, Nigel Walker
  • N-substituted glutamic acid derivatives with interleukin-1.beta. converting enzyme inhibitory activity
    Patent number: 5932549
    Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: August 3, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellschaft
    Inventors: Hamish John Allen, Subhashis Banerjee, Kenneth Dale Brady, John Cooke Hodges, Catherine Rose Kostlan, Robert Vincent Talanian
  • Hydroxamate inhibitors of interleukin-1.beta. converting enzyme
    Patent number: 5919790
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 6, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellsschaft
    Inventors: Hamish John Allen, Kenneth Dale Brady, Bradley William Caprathe, Paul Galatsis, John Lodge Gilmore, Sheryl Jeanne Hays, Robert Vincent Talanian, Nigel Walker, Joseph Scott Warmus
  • Organic-chemical compound with ice-inhibitory action
    Patent number: 5798247
    Abstract: Organic chemical compounds with ICE-inhibitory action which have structures such that they enter into an interaction with binding sites in a binding cavity.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: August 25, 1998
    Assignee: BASF Aktiengesellschaft
    Inventors: Hans-Peter Albrecht, Hans-Joachim Bohm, Kenneth Dale Brady, Peter Eckard, Kurt Ritter, Robert Vincent Talanian, Nigel Walker
  • N-substituted glutamic acid derivatives with interleukin-1 .beta. converting enzyme inhibitory activity
    Patent number: 5744451
    Abstract: The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1.beta. converting enzyme (ICE).
    Type: Grant
    Filed: August 13, 1996
    Date of Patent: April 28, 1998
    Assignees: Warner-Lambert Company, BASF A.G.
    Inventors: Hamish John Allen, Subhashis Banerjee, Kenneth Dale Brady, John Cooke Hodges, Catherine Rose Kostlan, Robert Vincent Talanian